Navigation Links
Letter from Alliqua CEO, Dave Johnston, to Shareholders
Date:3/7/2013

e such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies.

Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.

Contacts for Alliqua, Inc.  

Steven Berger
Chief Financial Officer
646-218-1450 
info@alliqua.com '/>"/>

SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. HealthEconomics.Com Announces Newsletter Promoting Health Outcomes and Pharma Reimbursement Jobs
2. HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
3. Topical BioMedics' Newsletter Dedicated to Natural Healing and Wellness--New Issue Available Online
4. First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection
5. Amarantus BioSciences Issues CEO Letter to Shareholders
6. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
7. Ronald L. Chez Files Amended 13D and Letter to the Board
8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
9. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
10. Genesis Biopharma Issues Letter To Shareholders
11. NeoStems CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... -- Bina Technologies, Inc. (Bina, Redwood City, ... been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).  ... that provides a big data platform for centralized management ... the academic and translational research markets.  Bina will be ... to focus on development of their innovative genomic analysis ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service ... detailed assessment on technological advancements and market for ... 1. The Smart Fabrics market is expected ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... , , SOUTH SAN ... SNSS ) reported today that it received a letter, dated September ... NASDAQ Stock Market notifying Sunesis that it does not comply with ... NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2). The ...
... , SAN DIEGO, Sept. 18, 2009 ... today that the company is scheduled to present at the UBS ... Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel ... Officer, is scheduled to provide an overview of the company, including ...
... PRINCETON, N.J., Sept. 18 Covance Inc. (NYSE: ... Global Life Sciences Conference on Monday, September 21, 2009 at 10:00 ... presentation at www.covance.com . In order to ... early. , , Covance, with headquarters in Princeton, ...
Cached Biology Technology:Sunesis Pharmaceuticals Receives NASDAQ Notification 2Sunesis Pharmaceuticals Receives NASDAQ Notification 3Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 2Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... hadrosaur (duck-billed) dinosaur the oldest duck-billed dinosaur known ... who expect the discovery to shed new light on ... gagslarsoni , the name given to the new dinosaur, ... to later duck-billed relatives. Acristavus means "non-crested ...
... PASADENA, Calif.Artificial intelligence has been the inspiration for countless ... countless scientists and engineers. Researchers at the California Institute ... toward creating artificial intelligencenot in a robot or a ... are the first to have made an artificial neural ...
... SALT LAKE CITY A team of researchers from the ... mouse model of focal dermal hypoplasia, a rare human birth ... This animal model not only provides insight into studying the ... novel way to study a signaling pathway that is crucial ...
Cached Biology News:New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality 2Caltech researchers create the first artificial neural network out of DNA 2Caltech researchers create the first artificial neural network out of DNA 3Caltech researchers create the first artificial neural network out of DNA 4Animal model sheds light on rare genetic disorder, signaling pathway 2
Human Cell Line Slides...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
Biology Products: